Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and conditions. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” —Thus, It Has Been Proven.

List your booth number for exhibitions, ask us